



Published in final edited form as:

*Cancer Epidemiol.* 2023 June ; 84: 102371. doi:10.1016/j.canep.2023.102371.

## Breast, cervical, and colorectal cancer screening test use in the US territories of Guam, Puerto Rico, and the US Virgin Islands

Sameer V. Gopalani<sup>a,b</sup>, Ashwini Soman<sup>c</sup>, Jean A. Shapiro<sup>a</sup>, Jacqueline W. Miller<sup>a</sup>, Karen J. Ortiz-Ortiz<sup>d</sup>, Maira A. Castañeda-Avila<sup>e</sup>, Lee E. Buenconsejo-Lum<sup>f</sup>, Lyña E. Fredericks<sup>g</sup>, Guillermo Tortolero-Luna<sup>d</sup>, Mona Saraiya<sup>a</sup>

<sup>a</sup>Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA

<sup>b</sup>Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA

<sup>c</sup>Cyberdata Technologies, Inc., Herndon, VA, USA

<sup>d</sup>Division of Cancer Control and Population Sciences, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, USA

<sup>e</sup>Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA

<sup>f</sup>John A Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI, USA

<sup>g</sup>Division of Chronic Disease and Prevention, US Virgin Islands Department of Health, St. Thomas, USVI, USA

### Abstract

**Background:** The United States Preventive Services Task Force (USPSTF) recommends breast, cervical, and colorectal cancer screening among eligible adults, but information on screening use in the US territories is limited.

**Methods:** To estimate the proportion of adults up-to-date with breast, cervical, and colorectal cancer screening based on USPSTF recommendations, we analyzed Behavioral Risk Factor Surveillance System data from 2016, 2018, and 2020 for the 50 US states and DC (US) and US territories of Guam and Puerto Rico and from 2016 for the US Virgin Islands. Age-standardized

---

**Corresponding author:** Mona Saraiya, Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, MS S107-4, Atlanta, GA 30341, Phone: 770-488-4293 (office) | msaraiya@cdc.gov.

CRedit authorship contribution statement:

Sameer V. Gopalani: conceptualization, methodology, writing - original draft

Ashwini Soman: methodology, formal analysis, writing - review & editing

Jean A. Shapiro: methodology, writing - review & editing

Jacqueline W. Miller: methodology, writing - review & editing

Karen J. Ortiz-Ortiz: writing - review & editing

Maira A. Castañeda-Avila: writing - review & editing

Lee E. Buenconsejo-Lum: writing - review & editing

Lyña E. Fredericks: writing - review & editing

Guillermo Tortolero-Luna: writing - review & editing

Mona Saraiya: conceptualization, methodology, supervision, writing - review & editing

Appendix A. Supplementary material

weighted proportions for up-to-date cancer screening were examined overall and by select characteristics for each jurisdiction.

**Results:** Overall, 67.2% (95% CI: 60.6–73.3) of women aged 50–74 years in the US Virgin Islands, 74.8% (70.9–78.3) in Guam, 83.4% (81.7–84.9) in Puerto Rico, and 78.3% (77.9–78.6) in the US were up-to-date with breast cancer screening. For cervical cancer screening, 71.1% (67.6–74.3) of women aged 21–65 years in Guam, 81.3% (74.6–86.5) in the US Virgin Islands, 83.0% (81.7–84.3) in Puerto Rico, and 84.5% (84.3–84.8) in the US were up-to-date. For colorectal cancer screening, 45.2% (40.0–50.5) of adults aged 50–75 years in the US Virgin Islands, 47.3% (43.6–51.0) in Guam, 61.2% (59.5–62.8) in Puerto Rico, and 69.0% (68.7–69.3) in the US were up-to-date. Adults without health care coverage reported low test use for all three cancers in all jurisdictions. In most jurisdictions, test use was lower among adults with less than a high school degree and an annual household income of <\$25,000.

**Conclusion:** Cancer screening test use varied between the US territories, highlighting the importance of understanding and addressing territory-specific barriers. Test use was lower among groups without health care coverage and with lower income and education levels, suggesting the need for targeted evidence-based interventions.

## Keywords

Cancer screening; breast cancer; cervical cancer; colorectal cancer; US territories

---

## 1. Introduction

Little is known about cancer screening prevalence and associated factors in the US territories despite evidence that mortality for most screenable cancers is generally higher in the territories than in the US states. Higher mortality rates for colorectal cancer among men have been reported in the US territories compared to the US states [1]. From 2008 to 2012, the age-standardized mortality rate for colorectal cancer per 100,000 was relatively higher among men in the US Virgin Islands (12.3) and Puerto Rico (11.8) compared to the US states (10.6) [1]. During the same period, the age-standardized mortality rate per 100,000 women for cervical cancer was relatively higher among women in Puerto Rico (1.9) than in the US states (1.7) [1]. In addition, the indigenous persons of Guam, Chamorros, had relatively higher age-standardized mortality rates per 100,000 for breast (32.0 vs. 28.0), colorectal (28.6 vs. 19.7), and cervical (7.5 vs. 2.6) cancers compared to the US states [2].

Screening followed by timely follow-up and treatment has been shown to reduce mortality for breast [3], cervical [4], and colorectal [5, 6] cancers. The United States Preventive Services Task Force (USPSTF) recommends breast [7], cervical [8], and colorectal [9] cancer screening among eligible adults. The limited number of studies on cancer screening prevalence and associated factors in the US territories focused primarily on breast cancer screening and how screening proportions varied [10, 11]. For instance, mammography use among Medicare beneficiaries in the US territories (34%) was approximately half of the use reported in the US (66%) [10].

The US Virgin Islands, Puerto Rico, and Guam are unincorporated, organized territories of the US, and their residents are US citizens. The US Virgin Islands (approximately 87,000 persons) and Puerto Rico (approximately 3,285,000 persons) are in the Caribbean, and Guam (approximately 153,000 persons) is in the Pacific Ocean. The US territories face geographical, economic, and technical challenges in providing cancer screening and follow-up services [12, 13]. Residents of these territories also experience several barriers accessing health care [14, 15]. All these factors combined can influence cancer screening test use. This study examined the proportion of eligible adults who were up-to-date with recommendations for breast, cervical, and colorectal cancer screening test use in the US territories and the 50 US states and the District of Columbia (henceforth referred to as the US).

## 2. Methods

### 2.1. Data source

The Behavioral Risk Factor Surveillance System (BRFSS) collects data from only three US territories (Guam, Puerto Rico, and the US Virgin Islands). Data from 2016, 2018, and 2020 were analyzed for the US and the US territories of Guam and Puerto Rico, and from 2016, the only year available, for the US Virgin Islands. BRFSS is an ongoing, random-digit-dialed telephone survey that collects information about health behaviors, chronic conditions, and the use of preventive health services. The survey uses a multistage sampling design to select a representative sample of noninstitutionalized adults aged 18 years residing within each US state, the District of Columbia, and three territories. Information about the BRFSS survey design, sampling, instrument, and data collection methods is available elsewhere [16]. In addition, information on the validity and reliability of the survey is provided elsewhere [17]. The median survey response rates from 2016, 2018, and 2020 were 47.1%, 49.9%, and 47.9%, respectively.

### 2.2. Measures

Up-to-date screening test use was defined based on the USPSTF recommendations for breast, cervical, and colorectal cancer screening in effect for the prior survey year (Table 1). Cancer screening questions for each survey year are provided in Appendix A (supplementary tables 1, 2, and 3).

### 2.3. Analysis

The weighted proportions of the population up-to-date for cancer screening were estimated overall and by select sociodemographic characteristics (age, race and ethnicity, education level, marital status, and household income), health care coverage, and smoking status. In addition, 95% confidence intervals (CIs) were calculated around the weighted proportions to allow comparison and indicate precision. Estimates of cancer screening test use were determined to be significantly different if the CIs for the estimates did not overlap. All estimates besides age were age-standardized to the 2000 US standard population using the direct method [20]. Non-age-standardized estimates of breast, cervical, and colorectal cancer screening test use for all jurisdictions are provided as supplementary material (supplementary tables 4, 5, and 6). Sampling weights and design parameters were applied

to account for the complex survey design and adjust for nonresponse [21]. Taylor series approximation methods were used to calculate variance estimates [22]. Estimates with a relative standard error (RSE) of greater than 30% were suppressed [23]. All analyses were conducted using SAS (version 9.4; SAS Institute, Inc.) and SUDAAN (version 11.0.3; RTI International).

### 3. Results

#### 3.1. Breast cancer screening

Overall, 67.2% (95% CI: 60.6–73.3) of women aged 50–74 years in the US Virgin Islands, 74.8% (70.9–78.3) in Guam, and 83.4% (81.7–84.9) in Puerto Rico were up-to-date with mammography (Table 2). In the US, 78.3% (77.9–78.6) of women were up-to-date. The proportion of women up-to-date with mammography did not differ by survey year within each jurisdiction.

Women without health care coverage reported low test use in Guam (41.8% [95% CI: 30.9–53.6]), the US Virgin Islands (45.1% [30.5–60.5]), the US (55.4% [52.7–58.1]), and Puerto Rico (57.8% [44.7–69.9]). In all jurisdictions except Puerto Rico, test use was lower among women whose annual household income was <\$25,000 compared to women whose income was \$50,000. In Puerto Rico and the US, test receipt was lower among people who smoke relative to people who never smoked or used to smoke.

#### 3.2. Cervical cancer screening

Overall, 71.1% (95% CI: 67.6–74.3) of women aged 21–65 years in Guam, 81.3% (74.6–86.5) in the US Virgin Islands, and 83.0% (81.7–84.3) in Puerto Rico were up-to-date with cervical cancer screening (Table 3). In the US, 84.5% (84.3–84.8) of women were up-to-date. Screening test use was low among women without health care coverage in Guam (47.7% [95% CI: 39.4–56.1]), the US (71.0% [69.8–72.1]), Puerto Rico (72.0% [65.2–77.9]), and the US Virgin Islands (73.9% [60.6–83.9]). Lower test use was also observed in Guam, Puerto Rico, and the US among women who were never married compared to those married or in a relationship, had less than a high school education compared to college graduates, or had an annual household income <\$25,000 compared to those with \$50,000. In Puerto Rico and the US, lower test receipt was reported among people who smoke compared to people who formerly smoked or never smoked.

#### 3.3. Colorectal cancer screening

Overall, 45.2% (95% CI: 40.0–50.5) of adults aged 50–75 years in the US Virgin Islands, 47.3% (43.6–51.0) in Guam, and 61.2% (59.5–62.8) in Puerto Rico were up-to-date with colorectal cancer screening. In the US, 69.0% (68.7–69.3) of adults were up-to-date. Compared to 2018, the proportion up-to-date with screening test use increased in 2020 for Puerto Rico (55.6% [95% CI: 52.9–58.2] to 71.8% [68.5–74.9]) and Guam (42.9% [37.3–48.7] to 55.9% [49.6–62.1]).

Colorectal cancer screening test use was very low among adults without health care coverage in all jurisdictions at 25.1% (95% CI: 14.6–39.5) in the US Virgin Islands, 25.4%

(17.6–35.0) in Guam, 31.2% (24.3–39.0) in Puerto Rico, and 40.8% (39.2–42.4) in the US. In all jurisdictions, test use was lower among adults with less than a high school education compared to college graduates and among adults with an annual household income of <\$25,000 compared to those with \$50,000. Compared to people who smoke, test receipt was lower among people who used to smoke or never smoked in Puerto Rico and the US.

Up-to-date colorectal and cervical cancer screening use did not differ when using the USPSTF screening recommendation definition in effect for the prior survey year (used in this analysis) compared to using a consistent USPSTF screening recommendation definition across the survey years, i.e., using the 2008 recommendation for colorectal cancer and the 2012 recommendation for cervical cancer for all survey years (data not shown).

#### 4. Discussion

Results from this study show that cancer screening test use varied across the territories, with higher use reported in Puerto Rico for breast and colorectal cancer screening tests. Compared to the US, colorectal cancer screening use was lower in all territories, breast cancer screening use was lower in the US Virgin Islands and higher in Puerto Rico, and cervical cancer screening use was lower in Guam and similar in Puerto Rico and the US Virgin Islands.

In addition to the unique geographical challenges [13], lower test use in the territories may be due to challenges to screening services [12] and disparities in health care funding and infrastructure [24]. Inadequate and capped federal grant and Medicaid funding in the US territories may have contributed to reduced access [25], fewer benefits [24], and poorer quality of care [26]. Access may have been further hampered by limited health care infrastructure, which has been exacerbated by natural disasters. For example, reductions in cervical cancer screening reported among Medicaid enrollees in Puerto Rico coincided with hurricanes in 2017 and earthquakes in 2020 [27]. Cancer screening and follow-up services in the US territories are also hampered by health care provider shortages caused by the difficulties in provider recruitment and retention [28]. In recent years, an exodus of providers in Puerto Rico has affected health care services [29]. In some territories, timely processing and receipt of screening results are hindered by a lack of certified laboratories and personnel combined with high costs for shipping and testing with off-island laboratories [12]. Obstacles to cancer screening in the US territories also include a lack of resources, low health literacy, transportation challenges, and cultural factors such as the resistance of male partners to having their female spouses examined for cervical cancer in some jurisdictions [13, 30].

Consistent with previous studies [31–33], adults without health care coverage had one of the lowest proportions of cancer screening use across all jurisdictions. Improving coverage could increase access to cancer screenings and improve test receipt. Screening use was also lower among adults with lower income levels, a disparity that has been shown to have persisted for years [31, 32, 34]. To improve access to screening in these groups, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast and cervical cancer screening to women who have a low income and are uninsured

or have inadequate insurance. For the 2016 to 2021 program years, NBCCEDP served approximately 1.1 million women with breast and cervical cancer screening and diagnostic services nationally [35]. In the same period, approximately 1,300 women were served in Guam and approximately 800 women were served in Puerto Rico through the NBCCEDP. In addition, federally qualified health centers (FQHCs) provide access to cancer screening services for underserved and low-income populations nationally and in the territories. Approximately 2,000 women in the US Virgin Islands and 1,450 women in Guam were screened for cervical cancer at FQHCs in 2020 [36, 37]. In the same year, approximately 700 adults each in the US Virgin Islands and Guam received colorectal cancer screening at an FQHC [36, 37].

Relative to 2018, reported up-to-date colorectal cancer screening use increased in 2020, especially in Puerto Rico and Guam. The increase in reported colorectal cancer screening use may be at least partially due to changes in the BRFSS questions. In 2020, questions about FIT-DNA and CT colonography were added to the BRFSS survey, and the wording of some questions was revised. The increase in colorectal screening use could also be partially explained by the increased use of home blood stool tests [38]. For instance, the use of fecal occult blood tests increased among Hispanic adults in Puerto Rico from 2019 to 2020 [39]. This increased use of home-based tests could have implications for cervical cancer screening, where home-based HPV self-sampling may be an option for increasing cervical cancer screening compliance. The increase in CRC screening use could also reflect the interventions, such as educational and health promotion programs [40, 41], implemented by the US territories to achieve the National Colorectal Cancer Roundtable screening goal of 80% in every community (previously 80% by 2018) [42]. One such intervention at the policy level was in Puerto Rico, where the Department of Health enacted an administrative order in 2015 to screen for colorectal cancer using the FIT annually [43].

Increasing cancer screening, especially among people who are medically underserved, is a national priority. The Community Preventive Services Task Force (CPSTF) recommends several evidence-based client- and provider-based interventions to improve cancer screening use. [44, 45]. For client-oriented interventions, CPSTF recommends the use of client reminders and one-on-one education. Lack of knowledge about cancer screening has been reported as a barrier in Guam [46], Puerto Rico [47], and US states [48], underscoring the need for one-on-one education and other educational interventions to inform individuals about the purpose, process, and benefits of screening. CPSTF also recommends reducing structural barriers to make screening easier for patients. During the SARS-CoV-2 pandemic, Guam BCCEDP made enrollment in their program easier, resulting in more women screened for breast and cervical cancer [49]. Provider-oriented interventions, such as provider assessment and feedback and provider reminder and recall systems, are recommended by CPSTF to improve cancer screening. Implementing multiple evidence-based interventions could also increase screening use. As guideline-concordant cancer screening use was lower among people who smoke in Puerto Rico and the US in this study and previous studies [50–53], education and counseling efforts could improve screening compliance in this group. Eligible patients who smoke should be encouraged to receive the recommended cancer screenings. Health care providers could also promote tobacco cessation interventions. In an analysis of the National Health Interview Survey, patients who attempted smoking cessation

were more likely to have received a colonoscopy, mammography, and Pap test than patients who had not [53], providing impetus to support cessation treatments as they may improve screening use.

#### 4.2. Limitations

The findings of this analysis are subject to some limitations. First, cancer screening use was self-reported; however, the accuracy of self-reported use has been generally high [54, 55], with some overreporting observed [56]. Second, BRFSS questions did not differentiate between screening and diagnostic tests. However, most tests are done for screening [31, 32]. Third, nonresponse bias could occur if there are systematic differences between respondents and nonrespondents; however, BRFSS has implemented raking as a weighting methodology to adjust for nonresponse [57]. Fourth, the wording of BRFSS survey questions about cancer screening tests has slightly changed over the survey years, which may affect screening test use estimates. A previous change in the BRFSS questionnaire wording for breast cancer screening reduced the estimated prevalence of mammography use, and the magnitude of the effect varied according to race and level of education [57]. Fifth, due to small sample sizes, some territory-specific estimates included wide confidence intervals. Lastly, BRFSS data for the US Virgin Islands was only available for 2016. Despite these limitations, this is one of the first studies to assess breast, cervical, and colorectal cancer screening test use for the US Virgin Islands, Puerto Rico, and Guam. The analyses benefitted from the most recent survey year with cancer screening questions and a large, population-based sample for comparison.

### 5. Conclusion

In this study, cancer screening test use varied between the territories. These findings highlight the importance of investigating and understanding territory-specific barriers and facilitators to tailor interventions for improving screening use. These findings also demonstrate the importance of population-based surveillance of cancer screening. Continued surveillance is needed to monitor trends, understand disparities, and measure progress against national cancer screening targets. Future work could focus on examining cancer screening test use in other US territories and the US-Affiliated Pacific Islands, which also face significant health disparities and have limited financial and health resources. In this study, test receipt was found to be lower among groups without health care coverage and with lower income and education levels, indicating a possible need for targeted evidence-based efforts. Failure to enhance screening use in these communities may widen disparities. Finally, findings from this study can be used to understand the changes in cancer screening use over time, aiding in measuring progress.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements:

This project was supported in part by an appointment (SVG) to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an

interagency agreement between the United States Department of Energy and the Centers for Disease Control and Prevention.

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

#### Funding:

M.A. Castaneda-Avila is supported by the National Cancer Institute's Prevention and Control of Cancer: Training for Change in Individuals and Systems (T32 CA172009).

#### Conflict of Interest:

Authors declare no conflicts of interest related to the content of this work.

Dr. Ortiz-Ortiz reported receiving grants from Abbvie Corp. and Merck Co. outside the submitted work.

#### Abbreviations:

|               |  |
|---------------|--|
| <b>BRFSS</b>  | Behavioral Risk Factor Surveillance System   |
| <b>USPSTF</b> | United States Preventive Services Task Force |

#### REFERENCES

- [1]. Razzaghi H, Quesnel-Crooks S, Sherman R, Joseph R, Kohler B, Andall-Brereton G, Ivey MA, Edwards BK, Mery L, Gawryszewski V, Saraiya M, Leading Causes of Cancer Mortality - Caribbean Region, 2003-2013, *MMWR Morb Mortal Wkly Rep* 65(49) (2016) 1395–1400. [PubMed: 27977639]
- [2]. Haddock RL, Talon RJ, Whippy HJ, Ethnic disparities in cancer mortality among residents of Guam, *Asian Pac J Cancer Prev* 7(3) (2006) 411–4. [PubMed: 17059333]
- [3]. Independent UK Panel on Breast Cancer Screening, The benefits and harms of breast cancer screening: an independent review, *The Lancet* 380(9855) (2012) 1778–1786.
- [4]. IARC Working Group, Cervix cancer screening, IARC Press, Lyon, 2005.
- [5]. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F, Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, *N Engl J Med* 328(19) (1993) 1365–71. [PubMed: 8474513]
- [6]. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD, Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy, *N Engl J Med* 366(25) (2012) 2345–57. [PubMed: 22612596]
- [7]. Siu AL, Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, *Annals of Internal Medicine* 164(4) (2016) 279–296. [PubMed: 26757170]
- [8]. US Preventive Services Task Force, Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement, *JAMA* 320(7) (2018) 674–686. [PubMed: 30140884]
- [9]. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr., García FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL, Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement, *Jama* 315(23) (2016) 2564–2575. [PubMed: 27304597]
- [10]. Layne TM, Aminawung JA, Soulos PR, Nunez-Smith M, Nunez MA, Jones BA, Wang KH, Gross CP, Quality Of Breast Cancer Care In The US Territories: Insights From Medicare, *Health Aff (Millwood)* 37(3) (2018) 421–428. [PubMed: 29505365]

- [11]. Lopez D, Miles RC, Flores EJ, Lehman CD, Narayan AK, Breast Cancer Screening in Puerto Rico and Other US Territories: Findings from the 2016 Behavioral Risk Factor Surveillance System Survey, *J Health Care Poor Underserved* 31(1) (2020) 340–352. [PubMed: 32037335]
- [12]. Senkomago V, Royalty J, Miller JW, Buenconsejo-Lum LE, Benard VB, Saraiya M, Cervical cancer screening in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in four US-Affiliated Pacific Islands between 2007 and 2015, *Cancer Epidemiol* 50(Pt B) (2017) 260–267. [PubMed: 29120834]
- [13]. Waxman AG, Buenconsejo-Lum LE, Cremer M, Feldman S, Ault KA, Cain JM, Diaz ML, Cervical Cancer Screening in the United States-Affiliated Pacific Islands: Options and Opportunities, *J Low Genit Tract Dis* 20(1) (2016) 97–104. [PubMed: 26704332]
- [14]. Blewett LA, Call KT, Marmor S, Health reform and the US Virgin Islands: high-need-limited impact, *J Public Health Manag Pract* 19(5) (2013) 393–401. [PubMed: 23446878]
- [15]. Ichiho HM, Gillan JW, Aitaoto N, An assessment of non-communicable diseases, diabetes, and related risk factors in the Territory of Guam: a systems perspective, *Hawaii J Med Public Health* 72(5 Suppl 1) (2013) 68–76. [PubMed: 23900408]
- [16]. Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2022. <https://www.cdc.gov/brfss/index.html>. (Accessed July 30 2022).
- [17]. Pierannunzi C, Hu SS, Balluz L, A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004–2011, *BMC Medical Research Methodology* 13(1) (2013) 49. [PubMed: 23522349]
- [18]. Moyer VA, Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement, *Annals of Internal Medicine* 156(12) (2012) 880–891. [PubMed: 22711081]
- [19]. Preventive US Services Task Force, Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement, *Ann Intern Med* 149(9) (2008) 627–37. [PubMed: 18838716]
- [20]. Klein RJ, Schoenborn CA, Age adjustment using the 2000 projected U.S. population, *Healthy People 2010 Stat Notes* (20) (2001) 1–10.
- [21]. Iachan R, Pierannunzi C, Healey K, Greenlund KJ, Town M, National weighting of data from the Behavioral Risk Factor Surveillance System (BRFSS), *BMC Med Res Methodol* 16(1) (2016) 155. [PubMed: 27842500]
- [22]. Research Triangle Institute, SUDAAN Language Manual, Volumes 1 and 2, Release 11, Research Triangle Institute, Research Triangle Park, NC, 2012.
- [23]. Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System. Comparability of Data BRFSS 2020, 2021. [https://www.cdc.gov/brfss/annual\\_data/2020/pdf/compare-2020-508.pdf](https://www.cdc.gov/brfss/annual_data/2020/pdf/compare-2020-508.pdf). (Accessed January 26 2022).
- [24]. Rodríguez-Vilá O, Nuti SV, Krumholz HM, Healthcare Disparities Affecting Americans in the US Territories: A Century-Old Dilemma, *Am J Med* 130(2) (2017) e39–e42. [PubMed: 27593609]
- [25]. Rivera-González AC, Roby DH, Stimpson JP, Bustamante AV, Purtle J, Bellamy SL, Ortega AN, The Impact of Medicaid Funding Structures on Inequities in Health Care Access for Latinos in New York, Florida, and Puerto Rico, *Health Serv Res* (2022).
- [26]. Rivera-Hernandez M, Leyva B, Keohane LM, Trivedi AN, Quality of Care for White and Hispanic Medicare Advantage Enrollees in the United States and Puerto Rico, *JAMA Intern Med* 176(6) (2016) 787–94. [PubMed: 27111865]
- [27]. Ortiz AP, Gierbolini-Bermúdez A, Ramos-Cartagena JM, Colón-López V, Sonawane K, Deshmukh AA, Ortiz-Ortiz KJ, Cervical Cancer Screening Among Medicaid Patients During Natural Disasters and the COVID-19 Pandemic in Puerto Rico, 2016 to 2020, *JAMA Netw Open* 4(10) (2021) e2128806. [PubMed: 34652451]
- [28]. Stolyar L, Tolbert J, Corallo B, Rudowitz R, Sharac J, Shin P, Rosenbaum S, Community Health Centers in the U.S. Territories and the Freely Associated States, 2021. <https://www.kff.org/report-section/community-health-centers-in-the-u-s-territories-and-the-freely-associated-states-issue-brief/>. (Accessed November 30 2022).

- [29]. Benavides X, Disparate health care in Puerto Rico: a battle beyond statehood, *U. Pa. JL & Soc. Change* 23 (2020) 163.
- [30]. American College of Obstetricians and Gynecologists, Committee Opinion No. 624: Cervical cancer screening in low-resource settings, *Obstet Gynecol* 125(2) (2015) 526–528. [PubMed: 25611643]
- [31]. Sabatino SA, Thompson TD, White MC, Shapiro JA, Clarke TC, Crosswell JM, Richardson LC, Cancer Screening Test Use-U.S., 2019, *Am J Prev Med* (2022).
- [32]. Sabatino SA, Thompson TD, White MC, Shapiro JA, de Moor J, Doria-Rose VP, Clarke T, Richardson LC, Cancer Screening Test Receipt - United States, 2018, *MMWR Morb Mortal Wkly Rep* 70(2) (2021) 29–35. [PubMed: 33444294]
- [33]. Suk R, Hong Y-R, Rajan SS, Xie Z, Zhu Y, Spencer JC, Assessment of US Preventive Services Task Force Guideline–Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019, *JAMA Network Open* 5(1) (2022) e2143582–e2143582. [PubMed: 35040970]
- [34]. Ortiz AP, Hebl S, Serrano R, Fernandez ME, Suárez E, Tortolero-Luna G, Factors associated with cervical cancer screening in Puerto Rico, *Prev Chronic Dis* 7(3) (2010) A58. [PubMed: 20394697]
- [35]. National Breast and Cervical Cancer Early Detection Program, National Aggregate. Five-Year Summary: January 2016 to December 2020, 2022. [https://www.cdc.gov/cancer/nbccedp/data/summaries/national\\_aggregate.htm](https://www.cdc.gov/cancer/nbccedp/data/summaries/national_aggregate.htm). (Accessed September 10 2022).
- [36]. Health Resources & Services Administration, Health Center Program UDS Data Overview. Guam, 2022. <https://data.hrsa.gov/tools/data-reporting/program-data?grantNum=H80CS02468>. (Accessed January 03 2023).
- [37]. Health Resources & Services Administration, Health Center Program UDS Data Overview. U.S. Virgin Islands, 2022. <https://data.hrsa.gov/tools/data-reporting/program-data?grantNum=H80CS00373>. (Accessed January 03 2023).
- [38]. Fedewa SA, Star J, Bandi P, Minihan A, Han X, Yabroff KR, Jemal A, Changes in Cancer Screening in the US During the COVID-19 Pandemic, *JAMA Network Open* 5(6) (2022) e2215490–e2215490. [PubMed: 35657622]
- [39]. Castaneda-Avila MA, Oyinbo AG, Epstein MM, Ortiz-Ortiz KJ, Tortolero-Luna G, Lapane KL, Trends and factors associated with fecal occult blood test utilization among Hispanic adults in Puerto Rico and the United States: BRFSS 2012–2020, *Cancer Prev Res (Phila)* (2023).
- [40]. Colón-López V, González D, Vélez C, Fernández-Espada N, Feldman-Soler A, Ayala-Escobar K, Ayala-Marín AM, Soto-Salgado M, Calo WA, Pattatucci-Aragón A, Rivera-Díaz M, Fernández ME, Community-Academic Partnership to Implement a Breast and Cervical Cancer Screening Education Program in Puerto Rico, *P R Health Sci J* 36(4) (2017) 191–197. [PubMed: 29220062]
- [41]. Colón-López V, Valencia-Torres IM, Ríos EI, Llavona J, Vélez-Álamo C, Fernández ME, Knowledge, Attitudes, and Beliefs About Colorectal Cancer Screening in Puerto Rico, *Journal of Cancer Education* (2022).
- [42]. Karlitz JJ, Oliphant A-LB, Greenwald DA, Pochapin MB, The American College of Gastroenterology and the 80% by 2018 Colorectal Cancer Initiative: A Multifaceted Approach to Maximize Screening Rates, *Official journal of the American College of Gastroenterology | ACG* 112(9) (2017) 1360–1362.
- [43]. Departamento de Salud, OA 334- Ordenar la Prueba de Detección de Sangre Oculta (03–10-15), 2015. <https://www.salud.gov.pr/CMS/8?TXTsearch=334>. (Accessed November 1 2022).
- [44]. Sabatino SA, Lawrence B, Elder R, Mercer SL, Wilson KM, DeVinney B, Melillo S, Carvalho M, Taplin S, Bastani R, Rimer BK, Vernon SW, Melvin CL, Taylor V, Fernandez M, Glanz K, Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services, *Am J Prev Med* 43(1) (2012) 97–118. [PubMed: 22704754]
- [45]. Community Preventive Services Task Force, Updated recommendations for client- and provider-oriented interventions to increase breast, cervical, and colorectal cancer screening, *Am J Prev Med* 43(1) (2012) 92–6. [PubMed: 22704753]

- [46]. Moss J, "Money talks. And the society we live in is very harsh." *Cancer Care-Seeking from the Perspectives of Guam's Chamorros*, *J Indig Soc Dev* 2(1) (2013).
- [47]. Colón-López V, Valencia-Torres IM, Ríos EI, Llavona J, Vélez-Álamo C, Fernández ME, Knowledge, Attitudes, and Beliefs About Colorectal Cancer Screening in Puerto Rico, *J Cancer Educ* (2022).
- [48]. Honein-AbouHaidar GN, Kastner M, Vuong V, Perrier L, Daly C, Rabeneck L, Straus S, Baxter NN, Systematic Review and Meta-study Synthesis of Qualitative Studies Evaluating Facilitators and Barriers to Participation in Colorectal Cancer Screening, *Cancer Epidemiology, Biomarkers & Prevention* 25(6) (2016) 907–917.
- [49]. Centers for Disease Control and Prevention, Guam Makes Program Enrollment Easier During the Pandemic, 2021. <https://www.cdc.gov/screenoutcancer/success/guam-makes-enrollment-easier.htm>. (Accessed September 10 2022).
- [50]. Eng VA, David SP, Li S, Ally MS, Stefanick M, Tang JY, The association between cigarette smoking, cancer screening, and cancer stage: a prospective study of the women's health initiative observational cohort, *BMJ Open* 10(8) (2020) e037945.
- [51]. Rakowski W, Clark MA, Ehrich B, Smoking and cancer screening for women ages 42–75: associations in the 1990–1994 National Health Interview Surveys, *Prev Med* 29(6 Pt 1) (1999) 487–95. [PubMed: 10600429]
- [52]. MacLaughlan SD, Lachance JA, Gjelsvik A, Correlation between smoking status and cervical cancer screening: a cross-sectional study, *J Low Genit Tract Dis* 15(2) (2011) 114–9. [PubMed: 21478697]
- [53]. Sanford NN, Sher DJ, Butler S, Xu X, Ahn C, D'Amico AV, Rebbeck T, Aizer AA, Mahal BA, Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010–2015, *JAMA Network Open* 2(5) (2019) e193759–e193759. [PubMed: 31099863]
- [54]. Anderson J, Bourne D, Peterson K, Mackey K, VA Evidence-based Synthesis Program Reports, Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening, Department of Veterans Affairs (US), Washington (DC), 2019.
- [55]. Vernon SW, Tiro JA, Vojvodic RW, Coan S, Diamond PM, Greisinger A, Fernandez ME, Reliability and validity of a questionnaire to measure colorectal cancer screening behaviors: does mode of survey administration matter?, *Cancer Epidemiol Biomarkers Prev* 17(4) (2008) 758–67. [PubMed: 18381467]
- [56]. Rauscher GH, Johnson TP, Cho YI, Walk JA, Accuracy of Self-Reported Cancer-Screening Histories: A Meta-analysis, *Cancer Epidemiology, Biomarkers & Prevention* 17(4) (2008) 748–757.
- [57]. Centers for Disease Control and Prevention, Methodologic changes in the Behavioral Risk Factor Surveillance System in 2011 and potential effects on prevalence estimates, *MMWR Morb Mortal Wkly Rep* 61(22) (2012) 410–3. [PubMed: 22672976]

**Highlights:**

- Cancer screening test use varied between the US territories.
- Breast cancer screening use was higher in Puerto Rico compared to the US states and other US territories.
- Cervical cancer screening use was comparable between the US states, Puerto Rico, and the US Virgin Islands and lower in Guam.
- Colorectal cancer screening use was lower in the US territories compared to the US states.
- Cancer screening test use was lower among adults without health care coverage in all jurisdictions.

**Table 1.**

Definitions of up-to-date cancer screening based on the United States Preventive Services Task Force recommendations.

| Screening         | Eligibility             | Survey year(s)   | Up-to-date definition <sup>1</sup>  |
|-------------------|-------------------------|------------------|---|
| Breast cancer     | Women aged 50-74 years  | 2016, 2018, 2020 | • Mammography within 2 years [7].   |
| Cervical cancer   | Women aged 21-65 years  | 2016, 2018       | • Pap test within 3 years for women aged 21-65 years <i>or</i><br>• Combination of Pap test and HPV test within 5 years for women aged 30-65 years [18].  |
|                   | Women aged 21-65 years  | 2020             | • Pap test within 3 years for women aged 21-65 years <i>or</i><br>• Combination of Pap test and HPV test within 5 years for women aged 30-65 years <i>or</i><br>• HPV test within 5 years for women aged 30-65 years [8]. |
| Colorectal cancer | Adults aged 50-75 years | 2016             | • Home blood stool test within 1 year <i>or</i><br>• Sigmoidoscopy within 5 years with a home blood stool test within 3 years <i>or</i><br>• Colonoscopy within 10 years [19].  |
|                   | Adults aged 50-75 years | 2018, 2020       | • Home blood stool test within 1 year <i>or</i><br>• Sigmoidoscopy or CT colonography <sup>2</sup> within 5 years <i>or</i><br>• Colonoscopy within 10 years <i>or</i><br>• FIT-DNA test <sup>2</sup> within 3 years [9]. |

**Abbreviations:** CT: computed tomography; DNA: deoxyribonucleic acid; FIT: fecal immunochemical test; HPV, human papillomavirus.

Notes:

<sup>1</sup> Behavioral Risk Factor Surveillance System survey questions on cancer screening for each survey year are provided in Appendix A.

<sup>2</sup> Behavioral Risk Factor Surveillance System survey questions on CT colonography and FIT-DNA test use were asked only during the 2020 survey year.

Table 2.

Age-specific and age-standardized<sup>a</sup> percentage of women up-to-date<sup>b</sup> with breast cancer screening in the US Virgin Islands, Guam, Puerto Rico, and the 50 US states and the District of Columbia, by select characteristics—Behavioral Risk Factor Surveillance System, 2016–2020.

|                                 | US Virgin Islands <sup>c</sup> |                     |     | Guam                |       |                     | Puerto Rico |                     |     | US <sup>d</sup>     |     |                     |
|---------------------------------|--------------------------------|---------------------|-----|---------------------|-------|---------------------|-------------|---------------------|-----|---------------------|-----|---------------------|
|                                 | No.                            | Weighted % (95% CI) | No. | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.         | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) |
| <b>Overall</b>                  | 324                            | 67.2 (60.6, 73.3)   | 968 | 74.8 (70.9, 78.3)   | 3,582 | 83.4 (81.7, 84.9)   | 271,112     | 78.3 (77.9, 78.6)   |     |                     |     |                     |
| <b>Survey year</b>              |                                |                     |     |                     |       |                     |             |                     |     |                     |     |                     |
| 2016                            | 324                            | 67.2 (60.6, 73.3)   | 274 | 73.8 (67.0, 79.6)   | 1,442 | 83.4 (80.4, 86.1)   | 105,393     | 78.2 (77.6, 78.7)   |     |                     |     |                     |
| 2018                            | _c                             | _c                  | 302 | 74.9 (67.9, 80.7)   | 1,099 | 83.2 (80.3, 85.7)   | 89,409      | 78.5 (77.9, 79.1)   |     |                     |     |                     |
| 2020                            | _c                             | _c                  | 392 | 75.8 (68.7, 81.8)   | 1,041 | 83.5 (80.7, 86.0)   | 76,310      | 78.2 (77.4, 78.9)   |     |                     |     |                     |
| <b>Age group (years)</b>        |                                |                     |     |                     |       |                     |             |                     |     |                     |     |                     |
| 50–59                           | 110                            | 63.4 (53.1, 72.6)   | 407 | 71.4 (65.7, 76.5)   | 1,352 | 80.7 (78.1, 83.1)   | 93,983      | 76.3 (75.7, 76.9)   |     |                     |     |                     |
| 60–69                           | 159                            | 74.1 (65.5, 81.3)   | 415 | 73.4 (64.3, 80.8)   | 1,555 | 85.3 (82.9, 87.3)   | 123,474     | 79.8 (79.3, 80.2)   |     |                     |     |                     |
| 70–74                           | 55                             | 72.1 (56.6, 83.7)   | 146 | 82.5 (74.5, 88.4)   | 675   | 86.1 (82.6, 89.0)   | 53,655      | 80.9 (80.2, 81.6)   |     |                     |     |                     |
| <b>Race/Ethnicity</b>           |                                |                     |     |                     |       |                     |             |                     |     |                     |     |                     |
| NH White                        | 38                             | 57.7 (39.3, 74.1)   | 83  | 82.5 (71.3, 90.0)   | 25    | 70.7 (50.1, 85.3)   | 213,206     | 77.5 (77.1, 77.8)   |     |                     |     |                     |
| NH Black                        | 226                            | 69.5 (61.6, 76.4)   | _h  | _h                  | _h    | _h                  | 24,607      | 84.0 (82.9, 85.0)   |     |                     |     |                     |
| NH Asian                        | _h                             | _h                  | 318 | 67.8 (60.8, 74.2)   | _h    | _h                  | 3,631       | 77.8 (74.1, 81.1)   |     |                     |     |                     |
| NH NHPI                         | _h                             | _h                  | 362 | 79.0 (73.5, 83.7)   | _h    | _h                  | 840         | 77.4 (67.4, 85.0)   |     |                     |     |                     |
| Hispanic                        | 40                             | 73.9 (55.0, 86.8)   | 74  | 77.9 (63.2, 87.9)   | 3,542 | 83.4 (81.8, 85.0)   | 15,584      | 79.9 (78.4, 81.4)   |     |                     |     |                     |
| <b>Education level</b>          |                                |                     |     |                     |       |                     |             |                     |     |                     |     |                     |
| Less than high school           | 40                             | 59.1 (40.9, 75.0)   | 63  | 71.0 (58.0, 81.3)   | 664   | 80.8 (76.1, 84.8)   | 14,980      | 73.0 (71.4, 74.5)   |     |                     |     |                     |
| High school graduate or GED     | 97                             | 70.6 (59.5, 79.6)   | 310 | 73.3 (66.4, 79.3)   | 901   | 83.3 (80.1, 86.1)   | 68,392      | 76.2 (75.5, 76.8)   |     |                     |     |                     |
| Some college                    | 70                             | 73.6 (61.1, 83.1)   | 303 | 71.0 (63.5, 77.5)   | 819   | 85.5 (82.7, 87.9)   | 78,408      | 78.0 (77.4, 78.6)   |     |                     |     |                     |
| College graduate                | 112                            | 74.2 (63.1, 82.9)   | 549 | 80.6 (75.0, 85.1)   | 1,195 | 84.1 (81.6, 86.3)   | 108,670     | 82.8 (82.2, 83.3)   |     |                     |     |                     |
| <b>Marital status</b>           |                                |                     |     |                     |       |                     |             |                     |     |                     |     |                     |
| Married or in a relationship    | 137                            | 68.3 (58.5, 76.7)   | 580 | 76.8 (71.9, 81.1)   | 1,843 | 85.2 (82.9, 87.2)   | 158,936     | 80.6 (80.2, 81.1)   |     |                     |     |                     |
| Previously married <sup>e</sup> | 119                            | 63.0 (52.3, 72.5)   | 310 | 73.1 (66.1, 79.2)   | 1,367 | 82.2 (79.6, 84.5)   | 89,931      | 74.3 (73.6, 74.9)   |     |                     |     |                     |

|   | US Virgin Islands <sup>c</sup> |                     |          | Guam                |       |                     | Puerto Rico |                     |     | US <sup>d</sup>     |     |                     |
|---|--------------------------------|---------------------|----------|---------------------|-------|---------------------|-------------|---------------------|-----|---------------------|-----|---------------------|
|   | No.                            | Weighted % (95% CI) | No.      | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.         | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) |
| Never married                           | 63                             | 75.9 (61.8, 85.9)   | 77       | 54.5 (42.1, 66.4)   | 358   | 80.6 (75.4, 85.0)   | 20,327      | 75.5 (74.2, 76.7)   |     |                     |     |                     |
| <b>Income level<sup>f</sup></b>         |                                |                     |          |                     |       |                     |             |                     |     |                     |     |                     |
| <\$25,000                               | 90                             | 53.8 (42.1, 65.0)   | 260      | 66.1 (58.6, 72.9)   | 2,186 | 83.2 (81.0, 85.1)   | 53,793      | 71.4 (70.6, 72.2)   |     |                     |     |                     |
| \$25,000-\$49,999                       | 87                             | 71.4 (58.6, 81.4)   | 237      | 79.4 (72.0, 85.2)   | 508   | 86.3 (82.2, 89.6)   | 53,993      | 76.1 (75.2, 77.0)   |     |                     |     |                     |
| 50,000                                  | 113                            | 80.0 (70.1, 87.2)   | 382      | 84.6 (78.4, 89.3)   | 214   | 80.8 (73.6, 86.4)   | 115,667     | 82.8 (82.2, 83.3)   |     |                     |     |                     |
| <b>Health care coverage<sup>g</sup></b> |                                |                     |          |                     |       |                     |             |                     |     |                     |     |                     |
| Yes                                     | 292                            | 74.1 (67.0, 80.2)   | 900      | 78.8 (75.0, 82.3)   | 3,508 | 84.2 (82.6, 85.7)   | 262,579     | 80.0 (79.6, 80.4)   |     |                     |     |                     |
| No                                      | 31                             | 45.1 (30.5, 60.5)   | 66       | 41.8 (30.9, 53.6)   | 72    | 57.8 (44.7, 69.9)   | 8,003       | 55.4 (52.7, 58.1)   |     |                     |     |                     |
| <b>Smoking status</b>                   |                                |                     |          |                     |       |                     |             |                     |     |                     |     |                     |
| Current smoker                          | <i>h</i>                       |                     | <i>h</i> | 74.7 (65.3, 82.3)   | 185   | 68.7 (60.4, 75.9)   | 30,817      | 65.2 (64.2, 66.2)   |     |                     |     |                     |
| Former smoker                           | 32                             | 50.2 (30.2, 70.2)   | 165      | 74.4 (64.7, 82.2)   | 560   | 84.5 (80.4, 87.9)   | 77,455      | 78.8 (78.2, 79.5)   |     |                     |     |                     |
| Never smoker                            | 282                            | 69.8 (62.8, 76.0)   | 671      | 74.7 (69.9, 79.0)   | 2,831 | 84.8 (83.0, 86.4)   | 161,225     | 81.3 (80.8, 81.7)   |     |                     |     |                     |

**Abbreviation:** CI, confidence interval; GED, General Educational Development; NH, non-Hispanic; NHPI, Native Hawaiian and Pacific Islander.

Notes:

<sup>a</sup> Age-standardized to the 2000 US standard population using the direct method.

<sup>b</sup> For all survey years, up-to-date screening was defined as receiving mammography within 2 years among women aged 50-74 years.

<sup>c</sup> Data only available for the 2016 survey year for the US Virgin Islands.

<sup>d</sup> 50 US states and the District of Columbia.

<sup>e</sup> Previously married includes divorced, widowed, and separated.

<sup>f</sup> Annual household income from all sources.

<sup>g</sup> Health care coverage includes health insurance, prepaid plans such as HMOs, or government plans such as Medicare.

<sup>h</sup> Estimate not reported as the relative standard error was greater than 30%.

Table 3.

Age-specific and age-standardized<sup>a</sup> percentage of women up-to-date<sup>b</sup> with cervical cancer screening in the US Virgin Islands, Guam, Puerto Rico, and the 50 US states, and the District of Columbia, by select characteristics—Behavioral Risk Factor Surveillance System, 2016-2020.

|                             | US Virgin Islands <sup>c</sup> |                     |       | Guam                |       |                     | Puerto Rico |                     |     | US <sup>d</sup>     |     |                     |
|-----------------------------|--------------------------------|---------------------|-------|---------------------|-------|---------------------|-------------|---------------------|-----|---------------------|-----|---------------------|
|                             | No.                            | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.         | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) |
| <b>Overall</b>              | 304                            | 81.3 (74.6, 86.5)   | 1,417 | 71.1 (67.6, 74.3)   | 4,337 | 83.0 (81.7, 84.3)   | 259,568     | 84.5 (84.3, 84.8)   |     |                     |     |                     |
| <b>Survey year</b>          |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| 2016                        | 304                            | 81.3 (74.6, 86.5)   | 436   | 69.5 (63.6, 74.8)   | 1,469 | 82.3 (79.8, 84.6)   | 86,873      | 84.7 (84.2, 85.1)   |     |                     |     |                     |
| 2018                        | _c                             | _c                  | 423   | 72.1 (66.0, 77.5)   | 1,396 | 83.0 (80.7, 85.1)   | 91,728      | 85.4 (84.9, 85.8)   |     |                     |     |                     |
| 2020                        | _c                             | _c                  | 558   | 71.7 (65.8, 76.9)   | 1,472 | 83.8 (81.7, 85.8)   | 80,967      | 83.6 (83.0, 84.1)   |     |                     |     |                     |
| <b>Age group (years)</b>    |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| 21-29                       | 29                             | 64.6 (45.7, 79.9)   | 197   | 65.6 (57.9, 72.5)   | 705   | 67.1 (63.4, 70.6)   | 35,761      | 71.9 (71.1, 72.7)   |     |                     |     |                     |
| 30-39                       | 55                             | 95.6 (86.5, 98.7)   | 340   | 78.0 (72.0, 83.1)   | 1,075 | 89.6 (87.3, 91.6)   | 57,851      | 90.0 (89.5, 90.4)   |     |                     |     |                     |
| 40-49                       | 59                             | 82.2 (61.9, 93.0)   | 341   | 68.3 (59.9, 75.7)   | 1,036 | 87.2 (84.4, 89.6)   | 56,415      | 88.4 (87.8, 88.9)   |     |                     |     |                     |
| 50-59                       | 89                             | 78.8 (67.7, 86.9)   | 343   | 73.9 (67.0, 79.8)   | 952   | 85.2 (82.3, 87.7)   | 66,214      | 86.0 (85.4, 86.5)   |     |                     |     |                     |
| 60-65                       | 72                             | 79.2 (67.0, 87.6)   | 196   | 64.8 (52.0, 75.8)   | 569   | 82.3 (78.1, 85.8)   | 43,327      | 82.5 (81.7, 83.3)   |     |                     |     |                     |
| <b>Race/Ethnicity</b>       |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| NH White                    | 31                             | 91.4 (81.1, 96.4)   | 124   | 84.6 (75.5, 90.7)   | 32    | 95.7 (85.1, 98.9)   | 181,457     | 85.7 (85.4, 86.0)   |     |                     |     |                     |
| NH Black                    | 201                            | 83.2 (76.8, 88.1)   | _h    | _h                  | _h    | _h                  | 25,069      | 87.4 (86.6, 88.1)   |     |                     |     |                     |
| NH Asian                    | _h                             | _h                  | 446   | 70.2 (65.1, 74.9)   | _h    | _h                  | 6,268       | 74.4 (72.5, 76.1)   |     |                     |     |                     |
| NH NHPI                     | _h                             | _h                  | 543   | 70.0 (64.4, 75.1)   | _h    | _h                  | 1,407       | 78.0 (73.7, 81.8)   |     |                     |     |                     |
| Hispanic                    | 45                             | 75.3 (57.6, 87.2)   | 87    | 76.8 (68.0, 83.7)   | 4,280 | 83.0 (81.6, 84.3)   | 29,895      | 83.6 (82.7, 84.4)   |     |                     |     |                     |
| <b>Education level</b>      |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Less than high school       | 36                             | 77.8 (56.4, 90.4)   | 77    | 58.3 (47.4, 68.5)   | 326   | 75.9 (69.5, 81.4)   | 14,179      | 78.1 (76.8, 79.3)   |     |                     |     |                     |
| High school graduate or GED | 87                             | 73.8 (62.5, 82.7)   | 411   | 68.4 (63.1, 73.2)   | 899   | 82.4 (79.4, 85.0)   | 52,797      | 80.6 (79.9, 81.3)   |     |                     |     |                     |
| Some college                | 68                             | 93.1 (82.9, 97.4)   | 340   | 75.8 (70.4, 80.4)   | 1,205 | 82.3 (79.9, 84.5)   | 71,464      | 84.8 (84.3, 85.3)   |     |                     |     |                     |
| College graduate            | 109                            | 84.3 (75.1, 90.5)   | 587   | 81.0 (77.0, 84.5)   | 1,902 | 86.3 (84.5, 87.8)   | 120,623     | 89.0 (88.6, 89.3)   |     |                     |     |                     |
| <b>Marital status</b>       |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |

|   | US Virgin Islands <sup>c</sup> |                     |       | Guam                |       |                     | Puerto Rico |                     |     | US <sup>d</sup>     |     |                     |
|---|--------------------------------|---------------------|-------|---------------------|-------|---------------------|-------------|---------------------|-----|---------------------|-----|---------------------|
|   | No.                            | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.         | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) |
| Married or in a relationship            | 139                            | 90.7 (85.2, 94.3)   | 916   | 79.1 (75.2, 82.6)   | 2,333 | 87.0 (85.1, 88.6)   | 159,810     | 87.7 (87.4, 88.1)   |     |                     |     |                     |
| Previously married <sup>e</sup>         | 73                             | 85.9 (68.6, 94.4)   | 227   | 66.2 (55.4, 75.6)   | 950   | 83.4 (79.6, 86.7)   | 50,586      | 84.2 (83.2, 85.0)   |     |                     |     |                     |
| Never married                           | 89                             | 73.9 (59.1, 84.8)   | 272   | 56.1 (48.7, 63.3)   | 1,029 | 75.1 (71.8, 78.2)   | 47,658      | 79.7 (79.0, 80.4)   |     |                     |     |                     |
| <b>Income level<sup>f</sup></b>         |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| <\$25,000                               | 103                            | 81.6 (72.9, 87.9)   | 370   | 61.9 (55.3, 68.0)   | 2,564 | 81.6 (79.7, 83.3)   | 51,473      | 79.1 (78.4, 79.8)   |     |                     |     |                     |
| \$25,000-\$49,999                       | 79                             | 80.1 (69.2, 87.8)   | 352   | 74.2 (67.6, 79.9)   | 719   | 88.0 (85.2, 90.4)   | 47,711      | 83.3 (82.6, 84.0)   |     |                     |     |                     |
| \$50,000                                | 95                             | 87.8 (71.5, 95.3)   | 583   | 84.1 (80.0, 87.5)   | 401   | 92.4 (88.1, 95.2)   | 127,946     | 89.0 (88.6, 89.4)   |     |                     |     |                     |
| <b>Health care coverage<sup>g</sup></b> |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Yes                                     | 253                            | 83.8 (75.7, 89.5)   | 1,261 | 76.4 (72.8, 79.7)   | 4,135 | 83.7 (82.3, 84.9)   | 238,146     | 86.5 (86.3, 86.8)   |     |                     |     |                     |
| No                                      | 51                             | 73.9 (60.6, 83.9)   | 155   | 47.7 (39.4, 56.1)   | 199   | 72.0 (65.2, 77.9)   | 20,893      | 71.0 (69.8, 72.1)   |     |                     |     |                     |
| <b>Smoking status</b>                   |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Current smoker                          | <i>h</i>                       |                     | 217   | 65.4 (56.2, 73.6)   | 333   | 76.1 (69.2, 81.8)   | 37,374      | 80.4 (79.7, 81.1)   |     |                     |     |                     |
| Former smoker                           | 25                             | 96.1 (85.8, 99.0)   | 238   | 85.4 (79.3, 89.9)   | 485   | 87.1 (82.8, 90.5)   | 52,443      | 87.7 (87.0, 88.3)   |     |                     |     |                     |
| Never smoker                            | 270                            | 83.0 (77.5, 87.4)   | 961   | 68.8 (64.6, 72.7)   | 3,514 | 83.6 (82.2, 84.9)   | 168,612     | 84.9 (84.5, 85.3)   |     |                     |     |                     |

**Abbreviation:** CI, confidence interval; GED, General Educational Development; NH, non-Hispanic; NHPI, Native Hawaiian and Pacific Islander.

Notes:

<sup>a</sup> Age-standardized to the 2000 US standard population using the direct method.

<sup>b</sup> For the 2016 and 2018 survey years, up-to-date screening was defined as receiving a Pap test within 3 years for women aged 21–65 years or a combination of Pap test and human papillomavirus (HPV) test within 5 years for women aged 30–65 years. For the 2020 survey year, the definition was updated to include an HPV test within 5 years for women aged 30–65 years.

<sup>c</sup> Data only available for the 2016 survey year for the US Virgin Islands.

<sup>d</sup> 50 US states and the District of Columbia.

<sup>e</sup> Previously married includes divorced, widowed, and separated.

<sup>f</sup> Annual household income from all sources.

<sup>g</sup> Health care coverage includes health insurance, prepaid plans such as HMOs, or government plans such as Medicare.

<sup>h</sup> Estimate not reported as the relative standard error was greater than 30%.

Table 4.

Age-specific and age-standardized<sup>a</sup> percentage of adults up-to-date<sup>b</sup> with colorectal cancer screening in the US Virgin Islands, Guam, Puerto Rico, and the 50 US states and the District of Columbia, by select characteristics—Behavioral Risk Factor Surveillance System, 2016-2020.

|                             | US Virgin Islands <sup>c</sup> |                     |       | Guam                |       |                     | Puerto Rico |                     |     | US <sup>d</sup>     |     |                     |
|-----------------------------|--------------------------------|---------------------|-------|---------------------|-------|---------------------|-------------|---------------------|-----|---------------------|-----|---------------------|
|                             | No.                            | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.         | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) |
| <b>Overall</b>              | 365                            | 45.2 (40.0, 50.5)   | 1,228 | 47.3 (43.6, 51.0)   | 4,546 | 61.2 (59.5, 62.8)   | 445,974     | 69.0 (68.7, 69.3)   |     |                     |     |                     |
| <b>Survey year</b>          |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| 2016                        | 365                            | 45.2 (40.0, 50.5)   | 314   | 43.8 (37.8, 50.0)   | 1,693 | 56.5 (53.9, 59.1)   | 164,245     | 67.0 (66.6, 67.4)   |     |                     |     |                     |
| 2018                        | _c                             | _c                  | 348   | 42.9 (37.3, 48.7)   | 1,272 | 55.6 (52.9, 58.2)   | 149,601     | 68.6 (68.1, 69.0)   |     |                     |     |                     |
| 2020                        | _c                             | _c                  | 566   | 55.9 (49.6, 62.1)   | 1,581 | 71.8 (68.5, 74.9)   | 132,128     | 71.4 (70.8, 71.9)   |     |                     |     |                     |
| <b>Age group (years)</b>    |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| 50-59                       | 101                            | 38.7 (30.6, 47.5)   | 451   | 40.3 (36.1, 44.6)   | 1,478 | 51.1 (48.7, 53.5)   | 134,290     | 59.3 (58.8, 59.8)   |     |                     |     |                     |
| 60-69                       | 164                            | 45.4 (38.1, 53.0)   | 569   | 53.4 (47.2, 59.6)   | 1,985 | 67.1 (64.4, 69.7)   | 204,005     | 75.8 (75.3, 76.1)   |     |                     |     |                     |
| 70-75                       | 100                            | 63.5 (51.1, 74.4)   | 208   | 51.4 (40.9, 61.7)   | 1,083 | 77.2 (73.8, 80.3)   | 107,679     | 82.7 (82.1, 83.2)   |     |                     |     |                     |
| <b>Sex</b>                  |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Male                        | 128                            | 44.3 (35.7, 53.3)   | 542   | 50.4 (45.0, 55.8)   | 1,708 | 60.4 (57.7, 63.1)   | 192,142     | 67.5 (67.1, 68.0)   |     |                     |     |                     |
| Female                      | 237                            | 45.9 (39.6, 52.3)   | 686   | 44.1 (39.6, 48.8)   | 2,838 | 61.8 (59.8, 63.7)   | 253,580     | 70.3 (69.9, 70.7)   |     |                     |     |                     |
| <b>Race/Ethnicity</b>       |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| NH White                    | 65                             | 53.7 (40.2, 66.6)   | 171   | 65.3 (55.9, 73.7)   | 29    | 45.8 (31.0, 61.4)   | 362,276     | 71.0 (70.7, 71.3)   |     |                     |     |                     |
| NH Black                    | 234                            | 46.6 (39.9, 53.3)   | _h    | _h                  | _h    | _h                  | 33,850      | 70.5 (69.6, 71.5)   |     |                     |     |                     |
| NH Asian                    | _h                             | _h                  | 362   | 42.8 (37.4, 48.4)   | _h    | _h                  | 5,874       | 63.9 (61.3, 66.5)   |     |                     |     |                     |
| NH NHPI                     | _h                             | _h                  | 409   | 43.9 (37.6, 50.3)   | _h    | _h                  | 1,130       | 63.7 (57.3, 69.7)   |     |                     |     |                     |
| Hispanic                    | 40                             | 37.1 (24.1, 52.3)   | 115   | 60.2 (49.6, 70.0)   | 4,501 | 61.3 (59.6, 62.9)   | 20,950      | 59.2 (57.8, 60.5)   |     |                     |     |                     |
| <b>Education level</b>      |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Less than high school       | 49                             | 27.8 (18.9, 38.8)   | 63    | 37.9 (28.0, 48.9)   | 825   | 55.6 (51.7, 59.4)   | 22,581      | 56.0 (54.8, 57.1)   |     |                     |     |                     |
| High school graduate or GED | 100                            | 46.2 (36.8, 55.9)   | 310   | 41.0 (35.7, 46.5)   | 1,132 | 58.6 (55.3, 61.9)   | 110,626     | 65.8 (65.3, 66.3)   |     |                     |     |                     |
| Some college                | 79                             | 62.2 (50.3, 72.7)   | 303   | 51.1 (45.1, 57.0)   | 1,035 | 63.6 (60.4, 66.7)   | 124,756     | 70.9 (70.4, 71.4)   |     |                     |     |                     |
| College graduate            | 130                            | 54.9 (46.8, 62.8)   | 549   | 60.3 (54.7, 65.0)   | 1,549 | 68.2 (65.7, 70.5)   | 187,208     | 75.5 (75.1, 76.0)   |     |                     |     |                     |

|   | US Virgin Islands <sup>c</sup> |                     |       | Guam                |       |                     | Puerto Rico |                     |     | US <sup>d</sup>     |     |                     |
|---|--------------------------------|---------------------|-------|---------------------|-------|---------------------|-------------|---------------------|-----|---------------------|-----|---------------------|
|   | No.                            | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.   | Weighted % (95% CI) | No.         | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) |
| <b>Marital status</b>                   |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Married or in a relationship            | 180                            | 47.0 (39.6, 54.6)   | 804   | 52.0 (47.9, 56.2)   | 2,642 | 64.0 (62.0, 66.0)   | 281,956     | 72.0 (71.6, 72.3)   |     |                     |     |                     |
| Previously married <sup>e</sup>         | 123                            | 42.8 (34.0, 52.1)   | 318   | 39.6 (33.4, 46.1)   | 1,472 | 59.0 (56.2, 61.8)   | 128,779     | 64.3 (63.8, 64.9)   |     |                     |     |                     |
| Never married                           | 61                             | 47.4 (34.7, 60.5)   | 104   | 51.5 (43.6, 59.3)   | 416   | 55.7 (50.2, 61.1)   | 33,302      | 61.5 (60.5, 62.5)   |     |                     |     |                     |
| <b>Income level<sup>f</sup></b>         |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| <\$25,000                               | 95                             | 33.6 (25.7, 42.7)   | 248   | 32.8 (27.3, 38.9)   | 2,611 | 58.3 (56.1, 60.4)   | 80,485      | 60.2 (59.5, 60.8)   |     |                     |     |                     |
| \$25,000-\$49,999                       | 103                            | 53.4 (42.5, 63.9)   | 287   | 53.1 (45.3, 60.9)   | 727   | 66.0 (62.3, 69.6)   | 88,488      | 65.4 (64.7, 66.2)   |     |                     |     |                     |
| \$50,000                                | 138                            | 54.8 (46.3, 63.2)   | 603   | 62.1 (57.1, 66.8)   | 393   | 69.9 (64.7, 74.6)   | 211,909     | 74.9 (74.5, 75.2)   |     |                     |     |                     |
| <b>Health care coverage<sup>g</sup></b> |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Yes                                     | 337                            | 50.4 (44.4, 56.4)   | 1,147 | 50.8 (46.9, 54.6)   | 4,455 | 62.6 (60.9, 64.3)   | 433,164     | 71.3 (71.0, 71.6)   |     |                     |     |                     |
| No                                      | 27                             | 25.1 (14.6, 39.5)   | 80    | 25.4 (17.6, 35.0)   | 90    | 31.2 (24.3, 39.0)   | 12,099      | 40.8 (39.2, 42.4)   |     |                     |     |                     |
| <b>Smoking status</b>                   |                                |                     |       |                     |       |                     |             |                     |     |                     |     |                     |
| Current smoker                          | 185                            | 48.3 (33.6, 63.3)   | 331   | 53.4 (46.1, 60.6)   | 1,068 | 64.1 (60.7, 67.5)   | 150,401     | 71.9 (71.4, 72.5)   |     |                     |     |                     |
| Former smoker                           | 59                             | 48.3 (33.6, 63.3)   | 331   | 53.4 (46.1, 60.6)   | 1,068 | 64.1 (60.7, 67.5)   | 150,401     | 71.9 (71.4, 72.5)   |     |                     |     |                     |
| Never smoker                            | 285                            | 46.1 (40.2, 52.2)   | 708   | 48.5 (43.8, 53.3)   | 3,158 | 62.3 (60.4, 64.1)   | 241,060     | 70.5 (70.1, 70.9)   |     |                     |     |                     |

**Abbreviation:** CI, confidence interval; GED, General Educational Development; NH, non-Hispanic; NHPI, Native Hawaiian and Pacific Islander.

Notes:

<sup>a</sup> Age-standardized to the 2000 US standard population using the direct method.

<sup>b</sup> For the 2016 survey year, up-to-date screening was defined as having a home blood stool test within 1 year, colonoscopy within 10 years, or sigmoidoscopy within 5 years with a home blood stool test within 3 years among adults aged 50-75 years. For the 2018 and 2020 survey years, up-to-date screening was defined as having a home blood stool test within 1 year, sigmoidoscopy or computed tomography colonography within 5 years, colonoscopy within 10 years, or fecal immunochemical test-DNA test within 3 years among adults aged 50-75 years.

<sup>c</sup> Data only available for the 2016 survey year for the US Virgin Islands.

<sup>d</sup> 50 US states and the District of Columbia.

<sup>e</sup> Previously married includes divorced, widowed, and separated.

<sup>f</sup> Annual household income from all sources.

<sup>g</sup> Health care coverage includes health insurance, prepaid plans such as HMOs, or government plans such as Medicare.

$\hat{\theta}_y$  Estimate not reported as the relative standard error was greater than 30%.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript